Abstract 4418
Background
High field iMRI with integrated neuronavigation system is an advanced diagnostic tool gives information about extent of resection allowing immediate update of neuronavigation parameters after anatomic changes occuring as a result of tumour resection, cerebrospinal fluid evacuation and brain shift.
Methods
20 CNS tumour cases underwent Brain suite MRI prior to surgery, then surgery was done after patient registration in navigation system using iMRI. Preoperative tumor volume was manually segmented, compared with intraoperative volume after first resection attempt and final post operative volume after surgical closure to calculate extent of resection (EOR).Descriptive statistics were used to find mean, SD, frequency, percentage of variables. Normally distributed interval data reported as means by two-sample t- test. Non-normally distributed interval/ordinal data reported as median{inter-quartile ranges} and compared among groups by Wilcoxon exact test to obtain EOR values.
Results
20 cases allocated to two groups (G), 1st in whom surgery was complete after first iMRI and 2nd who underwent further tumour removal. In G1 surgery was terminated in 11 cases after iMRI, GTR in 81.8% cases. iMRI showed subtotal resection(STR) in 18.2% patients but surgery stopped owing to infiltration of eloquent brain. Median preoperative tumour volume was 40.8cm3. Median postoperative tumour volume was 0.81cm3 with a significant p value (<0.001). Median EOR was 98.5% in G1. In G2, 9 of 20 (45%) underwent further resection of residual tumour after post resection iMRI. GTR in 77.7% and STR in 22.3%, because of tumour’s close proximity to eloquent brain area. Median % of tumour resection after the first iMRI was 82.65%. Median EOR from the final postoperative iMRI was 98.3%. GTR increased from 45% to 80 % after use of iMRI. Median % of residual tumour volume significantly decreased from 5.3% to 1.7 % (p value <0.001). Mean control tumour volume was 9.67% and final post operative volume of 4.72% , which is almost half of intraoperative tumour volume (p value <0.001).
Conclusions
iMRI has potential role in maximizing gross total resection rates of CNS tumours which has an overall great prognostic impact.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institutional ethics committee, Max Superspeciality Hospital, New Delhi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
860 - Dose differential modulation of the autophagic behavior of estrogen expressing breast carcinoma cells
Presenter: Mariam Fouad
Session: Poster Display session 1
Resources:
Abstract
2304 - Synthetic peptide of tumor–associated antigen L6 formulated with polymer-based adjuvant enhances anti-tumor effects in mice
Presenter: Shih-jen Liu
Session: Poster Display session 1
Resources:
Abstract
4419 - Improving detection level of somatic mosaicism in neurofibromatosis type 1
Presenter: Kristina Karandasheva
Session: Poster Display session 1
Resources:
Abstract
5283 - Preclinical pharmacokinetic/pharmacodynamic (PK/PD) relationship of ABN401, a highly selective Met inhibitor, in gastric and non-small-cell lung cancer models
Presenter: JooSeok Kim
Session: Poster Display session 1
Resources:
Abstract
5488 - Transcription factors of Snail family in the regulation of resistance of breast cancer cells to hypoxic conditions
Presenter: Alvina Khamidullina
Session: Poster Display session 1
Resources:
Abstract
5417 - Metastasis is impaired by endothelial-specific Dll4 loss-of-function through inhibition of epithelial-to-mesenchymal transition and reduction of cancer stem cells and circulating tumour cells
Presenter: Liliana Mendonça
Session: Poster Display session 1
Resources:
Abstract
5494 - Identification of novel and known FGFR gene fusions in Chinese non-small cell lung cancer
Presenter: Weixin Zhao
Session: Poster Display session 1
Resources:
Abstract
3412 - WNT pathway mutations (APC/CTNNB1) and immune checkpoint inhibitors (ICI) response in metastatic non-small cell lung cancer (NSCLC) patients.
Presenter: Francisco Javier Ros Montana
Session: Poster Display session 1
Resources:
Abstract
1815 - Leukocytosis as a negative prognostic factor in patients with lung cancer: Which subpopulation of leukocytes is responsible?
Presenter: Filip Kohutek
Session: Poster Display session 1
Resources:
Abstract
5022 - Identification of MET gene amplifications using next-generation sequencing in non-small cell lung cancer patients
Presenter: Sergi Clavé
Session: Poster Display session 1
Resources:
Abstract